Photo: Reuters
LONDON (Reuters) - Days after grabbing headlines with its COVID-19 "vaccine for the world", AstraZeneca is facing tricky questions about its success rate that some experts say could hinder its chances of getting speedy U.S. and E.U. regulatory approval.
Several scientists have raised doubts about the robustness of results showing the shot was 90% effective in a sub-group of trial participants who, by error initially, received a half dose followed by a full dose.
British drugmaker AstraZeneca said on Monday that its experimental vaccine, developed with Oxford University, prevented on average 70% of COVID-19 cases in late-stage trials in Britain and Brazil.
While the success rate was 90% in the sub-group of volunteers, the efficacy was 62% if the full dose was given twice, as it was for most participants.
That is well above the 50% efficacy required by U.S. regulators. Europe's drug regulator has said it will not set a minimum level of efficacy for potential vaccines.
The U.S. regulator, the Food and Drug Administration (FDA), has not commented on AstraZeneca's vaccine trial results.
The European Medicines Agency said on Thursday it would "assess data on the efficacy and safety of the vaccine in the coming weeks once they have been received from the company".
Read more from the original article:
27 Nov 2020, 09:27 を編集しました
免責事項：本記事で述べられている見解は著者の見解のみであり、Followmeの公式見解を反映するものではありません。Followmeは、提供された情報の正確性、完全性、信頼性について一切責任を負いません。また、書面で明示的に記載されている場合を除き、本記事の内容に基づいて行われたいかなる行動についても責任を負いません。
古いコメントはありません。ソファをつかむ最初のものになりましょう。